Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Source Summary

A personalized mRNA cancer vaccine demonstrated a 42% reduction in disease recurrence risk among melanoma patients compared to standard treatment. The vaccine represents a new approach to cancer immunotherapy using messenger RNA technology tailored to individual patients.

Why it matters

Personalized mRNA vaccines represent a potential advance in cancer treatment by reducing recurrence risk in melanoma, a serious skin cancer with high mortality rates.